rociletinib rociletinib rociletinib is a medication developed to treat non-small cell lung carcinomas with a specific mutation. it is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. it was being developed by clovis oncology as a potential treatment for non-small-cell lung cancer. in may 2016, development of rociletinib was halted, along with its associated clinical trials, and clovis oncology withdrew its marketing authorisation application from the european medicines agency. rociletinibclinical datatrade namesxegafriother namesco-1686, avl-301routes ofadministrationby mouthatc codel01eb05 (who) identifiers iupac name n-(3--5-(trifluoromethyl)-4-pyrimidinyl]amino}phenyl)acrylamide cas number1374640-70-6pubchem cid57335384drugbankdb11907chemspider30646712unii72ah61702gkeggd10858chemical and physical dataformulac27h28f3n7o3molar mass555.562 g·mol−13d model (jsmol)interactive image smiles cc(=o)n1ccn(cc1)c2ccc(c(c2)oc)nc3ncc(c(n3)nc4cccc(c4)nc(=o)c=c)c(f)(f)f inchi inchi=1s/c27h28f3n7o3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16h,1,10-13h2,2-3h3,(h,32,39)(h2,31,33,34,35)key:hufozjxakzvrnj-uhfffaoysa-n